New pill for baldness shows promise in Mid-Stage trial
NCT ID NCT06527365
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 29 times
Summary
This study tests an experimental oral drug called VDPHL01 for people with mild to moderate pattern baldness (androgenetic alopecia). About 70 men and women aged 18-65 will take the drug daily for 12 months. Researchers will measure changes in hair count and ask participants how they feel about their hair growth. The goal is to see if the drug is safe and effective for treating hair loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENETIC ALOPECIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
01
San Diego, California, 92123, United States
-
02
South Jordan, Utah, 84095, United States
-
03
Hackensack, New Jersey, 07601, United States
-
04
New Albany, Indiana, 47150, United States
Conditions
Explore the condition pages connected to this study.